Harbour BioMed has dosed the first patient in a China Phase III trial of its anti-FcRn antibody as a therapy for myasthenia gravis. In its Phase II proof -of-concept test, batoclimab showed statistically significant improvement in efficacy as well as a favorable safety and tolerability profile. HBM is developing batoclimab as a pipeline-in-a-product to treat multiple pathogenic-IgG mediated autoimmune diseases. Earlier this year, the candidate was granted Breakthrough Therapy Designation in China . HBM's business office is in Boston with drug discovery operations in Rotterdam and labs in Shanghai . More details.... Stock Symbol: (HK: 02142) Share this with colleagues: // //